Phase II study of the feasibility and safety of radium-223 dichloride in combination with hormonal therapy and denosumab for the treatment of patients with hormone receptor-positive breast cancer with bone-dominant metastasis

Authors
Category Primary study
JournalCancer Research
Year 2018
This article has no abstract
Epistemonikos ID: f15ee5cc2cca33f20a69bf84e90ebd9c046c1735
First added on: Feb 09, 2025